cemiplimab
Selected indexed studies
- Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. (Nat Med, 2022) [PMID:36008722]
- Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. (N Engl J Med, 2025) [PMID:40454639]
- Survival with Cemiplimab in Recurrent Cervical Cancer. (N Engl J Med, 2022) [PMID:35139273]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. (2022) pubmed
- Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. (2025) pubmed
- Survival with Cemiplimab in Recurrent Cervical Cancer. (2022) pubmed
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. (2021) pubmed
- Cemiplimab. (2006) pubmed
- First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. (2023) pubmed
- Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. (2023) pubmed
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. (2018) pubmed
- Cemiplimab. (2012) pubmed
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. (2022) pubmed